Drug Combination Details
| General Information of the Combination (ID: C87321) | |||||
|---|---|---|---|---|---|
| Name | Lycopene NP Info | + | T0901317 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Prostate cancer
[ICD-11: 2C82]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | ABCA1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | NR1H3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PPAR-gamma | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | ||
| PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Lycopene and the LXRalpha agonist T0901317 synergistically inhibit the proliferation of androgen-independent prostate cancer cells via the PPARgamma-LXRalpha-ABCA1 pathway. | |||||
